

Current Clinical Oncology
Series Editor: Maurie Markman

Antonio Giordano
Marcella Macaluso *Editors*

Gynecological Cancers

Genetic and Epigenetic Targets and Drug
Development

 Springer

Current Clinical Oncology

Maurie Markman, MD
Series Editor

More information about this series at <http://www.springer.com/series/7631>

Antonio Giordano • Marcella Macaluso
Editors

Gynecological Cancers

Genetic and Epigenetic Targets
and Drug Development

 Springer

Editors

Antonio Giordano, MD, PhD
Department of Biology
Temple University
Philadelphia, PA, USA

Marcella Macaluso, PhD
Department of Biology
Temple University
Philadelphia, PA, USA

Current Clinical Oncology

ISBN 978-3-319-32905-5

ISBN 978-3-319-32907-9 (eBook)

DOI 10.1007/978-3-319-32907-9

Library of Congress Control Number: 2016943122

© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature

The registered company is Springer International Publishing AG Switzerland

*The Editors, on behalf of all the contributors to this book,
dedicate this work to all the women who are fighting
with gynecologic cancers and to those involved in the research,
prevention, treatment, and care of these diseases.*

Preface

Over the years, the prevention and treatment of gynecologic cancers has improved as the result of strong multidisciplinary efforts, which allows for early detection of the disease and improved intervention strategies. In this book we have gathered all the molecular and cellular aspects of gynecological cancers together within one volume and provided a comprehensive resource of information on drug discovery and drug development for the treatment of these diseases.

The reader will find an overview of the genetic and epigenetic mechanisms underlying the formation and progression of gynecological cancers as well as detailed, up-to-date information on the etiology, diagnosis, and treatment of these diseases, which include ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, and vulvar cancer. Fertility preservation and available options were also included in the book. In addition, emphasis was placed in providing the public with information on the racial/ethnic disparities in the treatment of gynecological cancers.

Philadelphia, PA, USA

Antonio Giordano
Marcella Macaluso

Contents

Part I Epigenetic Mechanisms in Gynecological Cancers

- 1 Epigenetic Mechanisms in Gynecological Cancer** 3
Gavino Faa, Daniela Fanni, Giuseppina Pichiri,
and Clara Gerosa
- 2 Pharmacoepigenomics and Pharmacovigilance
in Gynecological Cancers** 23
Ang Sun

Part II Current Standard of Care for the Treatment of Gynecological Tumors

- 3 Advances in Cervical Cancer and Ongoing Clinical Trials**..... 51
Giuseppina D’Andrilli
- 4 Advances in Ovarian Cancer and Ongoing Clinical Trials**..... 65
Valeria Masciullo, Cristina di Cesare, and Ida Paris
- 5 Novel Methods for Prevention and Early Diagnosis
of Ovarian and Endometrial Cancers**..... 79
Roberto Piccoli, Nicoletta De Rosa, and Selina Davis

Part III Gynecological Cancers: New Therapies, Drug Development, and Challenges

- 6 Developmental Therapeutics for Gynecologic Cancers:
An Overview** 99
Jennifer L. Brown and Christina S. Chu

Part IV Fertility Preservation in the Setting of Malignant Disease

- 7 Preservation of Fertility in Gynecological Malignancies**..... 129
Janos L. Tanyi

**Part V Racial/Ethnic Disparities in Gynecological Cancer
Screening, Treatment and Survival**

**8 Racial/Ethnic Disparities in Gynecological Cancer
Screening, Treatment, and Survival 151**
Fong W. Liu, Robert E. Bristow, and Ana I. Tergas

Index..... 167

Contributors

Robert E. Bristow, MD, MBA Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California at Irvine, Orange, CA, USA

Jennifer L. Brown, MD Division of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Cristina di Cesare, MD Division Of Gynecologic Oncology, Agostino Gemelli Hospital, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome, Italy

Christina S. Chu, MD Division of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Giuseppina D'Andrilli, PhD Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, USA

Selina Davis, MD Department of Obstetrics and Gynecology, Albert Einstein Medical Center, Philadelphia, PA, USA

Gavino Faa, MD Dipartimento di Scienze Chirurgiche, Faculty of Medicine, Istituto di Anatomia Patologica, University Hospital San Giovanni di Dio, University of Cagliari, Cagliari, Italy

Daniela Fanni, MD, PhD Dipartimento di Scienze Chirurgiche, Faculty of Medicine, Istituto di Anatomia Patologica, University Hospital San Giovanni di Dio, University of Cagliari, Cagliari, Italy

Clara Gerosa, MD Dipartimento di Scienze Chirurgiche, Faculty of Medicine, Istituto di Anatomia Patologica, University Hospital San Giovanni di Dio, University of Cagliari, Cagliari, Italy

Fong W. Liu, MD, MPH Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Valeria Masciullo, MD, PhD Division of Gynecologic Oncology, Agostino Gemelli Hospital, Catholic University of Sacred Heart, Rome, Italy

Ida Paris, MD Division of Gynecologic Oncology, Agostino Gemelli Hospital, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome, Italy

Roberto Piccoli, MD Department of Gynecology, Outpatient Clinic Center “Piccoli”, Naples, Italy

Giuseppina Pichiri, BSc Dipartimento di Scienze Chirurgiche, Faculty of Medicine, Istituto di Anatomia Patologica, University Hospital San Giovanni di Dio, University of Cagliari, Cagliari, Italy

Nicoletta De Rosa, MD Department of Gynecology, Outpatient Clinic Center “Piccoli”, Naples, Italy

Ang Sun, PhD Fels Institute of Cancer Research and Molecular Biology, School of Medicine, Temple University, Philadelphia, PA, USA

Janos L. Tanyi, MD, PhD Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania Health System, Philadelphia, PA, USA

Ana I. Tergas, MD, MPH Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA

Part I

**Epigenetic Mechanisms
in Gynecological Cancers**

Gavino Faa, Daniela Fanni, Giuseppina Pichiri,
and Clara Gerosa

Abstract

The disruption of epigenetic regulatory mechanisms has been demonstrated to represent the prevalent carcinogenetic actor in cancer, aberrant epigenetic silencing of tumor suppressor genes, mainly due to DNA methylation, representing a relevant mechanism able of modifying the expression of key genes during carcinogenesis. In addition, epigenetic regulation has included microRNAs that regulate gene expression leading to inhibition and/or degradation of RNA target. In recent years, epigenetic silencing has been indicated as one of the major causes of gynecological cancer, being able to inactivate multiple pathways including cell cycle control, DNA repair, and apoptosis. In this chapter, the most important environmental factors interfering with the DNA methylation status in mammalian cells, leading to the insurgence of gynecological tumors will be discussed, including the dietary habits that have been indicated as main actors of DNA methylation. The role of epigenetics in the insurgence of ovarian cancer, endometrial cancer, cervical cancer, and endocervical cancer will be discussed. Finally, the role of microbioma in gynecological cancer insurgence and progression will be discussed. Here, a modern view of the relationship between genetics and epigenetics in gynecological cancer is presented. According to this view, genetics might be seen as a piano, a long one with a keyboard of 25,000 keys each one representing one human gene, whereas epigenetics could be represented by the piano tuner and by the pianist. The epigenetic approach is based on changing the pianist, i.e. the hyper- or hypomethylation status of target genes appears much more promising for the therapy of gynecological cancer than the previous ones based on modifying the piano, i.e. the genetic changes accumulating in tumor cells.

G. Faa, MD (✉) • D. Fanni • G. Pichiri • C. Gerosa
Dipartimento di Scienze Chirurgiche, Faculty of
Medicine, Istituto di Anatomia Patologica, University
Hospital San Giovanni di Dio, University of Cagliari,
Via Ospedale N. 56, Cagliari 09124, Italy
e-mail: gavinofaa@gmail.com